Related Experiment Video

Updated: Jun 3, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Targeting inhibitor of apoptosis proteins for therapeutic intervention

Chudi Ndubaku1, Frederick Cohen, Eugene Varfolomeev

  • 1Department of Medicinal Chemistry, Genentech, Inc., South San Francisco, CA 94080, USA.

Future Medicinal Chemistry
|March 24, 2011
PubMed

Insights

Inhibitors of apoptosis (IAP) proteins are key targets in cancer therapy. Targeting IAPs can overcome resistance to chemotherapy and radiation, offering new hope for cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Inhibitors of apoptosis (IAP) proteins are crucial regulators of programmed cell death.
  • Overexpression of IAPs contributes to cancer cell survival and resistance to apoptosis induced by standard therapies like radiation and chemotherapy.
  • IAPs also play roles in regulating NF-κB pathways, cell division, and evasion of death receptor-mediated apoptosis.

Purpose of the Study:

  • To review the therapeutic potential of targeting Inhibitors of Apoptosis (IAP) proteins in human malignancies.
  • To highlight the role of IAPs in cancer progression and treatment resistance.
  • To discuss current strategies for developing IAP-targeting cancer therapies.

Main Methods:

  • Review of existing literature on IAP proteins and their role in cancer.
  • Analysis of therapeutic strategies aimed at inhibiting IAP function.
  • Discussion of small molecule inhibitors, antisense oligonucleotides, and transcriptional repression as IAP-targeting approaches.

Main Results:

  • IAP proteins are frequently overexpressed in various cancers, promoting tumor cell survival.
  • Targeting IAPs can sensitize cancer cells to apoptosis, potentially overcoming resistance to conventional treatments.
  • Multiple strategies are being developed to inhibit IAP function for therapeutic benefit.

Conclusions:

  • Inhibitors of apoptosis (IAP) proteins represent promising therapeutic targets for human cancers.
  • Developing effective IAP-targeting agents could significantly improve treatment outcomes for cancer patients.
  • Further research into IAP-targeting strategies holds potential for novel cancer therapies.

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...